How Siemens Healthineers Built Its China Medical Device Business: Case Study

Siemens Healthineers has built China into its second-largest market globally, generating approximately €2.5 billion in annual revenue from the region as of fiscal 2023, representing roughly 13% of the company’s total global sales. The German MedTech giant’s success in China rests on a strategy that combines wholly-owned manufacturing operations through its 外商独资企业 (WFOE, wàishāng dúzī qǐyè), deep localization of R&D, and aggressive navigation of the Volume-Based Procurement (VBP, liàng cǎi, liàng cǎi) system. This case examines the key decisions, milestones, and pitfalls Siemens Healthineers encountered on its path to becoming one of China’s top three medical imaging and diagnostics providers.

The Cornerstone: Wholly-Owned Manufacturing and R&D

Siemens Healthineers first entered China through joint ventures in the 1990s, but shifted decisively toward full ownership after 2000. In 2014, the company opened its €300 million Shanghai Innovation Center, its largest R&D facility outside Germany, housing 1,200+ engineers. By 2022, the company operated three wholly-owned manufacturing sites in Shanghai, Wuxi, and Shenzhen, producing CT scanners, MRI systems, ultrasound devices, and X-ray machines specifically for the Chinese market.

This WFOE structure allowed Siemens Healthineers to retain 100% of its intellectual property, crucial in a sector where technology transfer requirements have historically been a barrier. According to company filings, its Chinese R&D team has filed over 1,800 patents as of 2023, including 450+ specifically for low-cost, high-volume diagnostic devices tailored to China’s grassroots hospitals under the “Healthy China 2030” initiative.

China’s medical imaging equipment market was valued at ¥148 billion (approximately €19 billion) in 2023, growing at a compound annual growth rate (CAGR) of 8.5% since 2020. Siemens Healthineers holds an estimated 22% market share in CT systems and 18% in MRI systems, placing it neck-and-neck with GE Healthcare and slightly ahead of Philips, according to China Chamber of Commerce for Medical Devices data. However, the competitive landscape includes increasingly capable domestic players like United Imaging (联影医疗, Liányǐng Yīliáo), which has captured 15-17% market share in category segments since 2020.

Conquering the VBP System: The “Tiered Price” Strategy

China’s Volume-Based Procurement (VBP) system, rolled out for medical devices in 2021, initially seemed a threat to foreign pricing power. Under VBP, provincial governments aggregate hospital purchasing to negotiate 50-70% price cuts on diagnostic equipment and consumables. Siemens Healthineers faced a stark choice: either lose market share to domestic rivals or participate in VBP with razor-thin margins.

The company devised a three-pronged response. First, it created a dedicated “China Value” product line — stripped-down versions of its high-end machines built in its Chinese factories using local supply chains. For example, the SOMATOM go.Up CT scanner, priced at ¥1.2 million (€155,000) versus the global standard model’s ¥3.5 million (€450,000), was designed specifically for VBP tenders in county-level hospitals. Second, Siemens Healthineers invested in consumables and service contracts — toner, replacement tubes, maintenance — where margins remained higher and VBP rules were less strict. Third, the company accelerated local production of critical components: by 2023, 65% of raw materials for its Chinese CT scanners were sourced domestically, up from 40% in 2020.

Key VBP Bid Results (Siemens Healthineers vs. Domestic Competitors, 2022-2023)

While Siemens Healthineers’ win rates in CT and MRI remained strong, the data reveals a sharp divergence in lower-tier equipment like X-ray and ultrasound, where domestic players undercut prices by an additional 20-30%. The company managed volume growth — selling 35% more units in VBP categories in 2023 versus 2021 — but saw overall profit margins on hardware compress from 28% to 17% over the same period.

Navigating the Regulatory Maze: NMPA Approvals and the “Green Channel”

China’s National Medical Products Administration (NMPA, guójiā yàopǐn jiāndū guǎnlǐ jú) requires separate clinical trials and registration for most imported medical devices — a process that typically takes 12-24 months versus 6-9 months for domestically manufactured equivalents. Siemens Healthineers’ WFOE structure gave it a decisive advantage: devices manufactured in its Chinese factories could be registered as “domestic products,” cutting approval timelines by 50-60%.

The company leveraged China’s “Green Channel” green channel (lǜsè tōngdào) for innovative medical devices, which accelerates NMPA review for products deemed “clinically urgently needed.” Between 2020 and 2023, Siemens Healthineers secured Green Channel designation for five products, including its AI-powered CT lung nodule detection system and a portable ultrasound for rural clinics. Each designation shaved 8-10 months off the standard approval cycle, translating to an estimated ¥50 million (€6.4M) in accelerated revenue per product.

A critical lesson emerged in 2022, when the company’s laboratory diagnostics division attempted to import a next-generation immunoassay analyzer from Germany. The NMPA required a full Chinese clinical trial involving 2,000 patients, consuming 22 months and ¥30 million (€3.9M). Siemens Healthineers subsequently relocated production of that analyzer to its Wuxi factory, completing the domestic re-registration in 10 months at ¥12 million (€1.5M). The faster timeline enabled the product to launch in time for the 2023 VBP cycle, capturing ¥200 million (€25.7M) in first-year sales.

Building the Channel Ecosystem: Distributors, Service, and Training

Siemens Healthineers sells approximately 70% of its medical devices in China through third-party distributors, a figure consistent with industry norms. However, the company has invested heavily in consolidating its distributor network — reducing from 580 active partners in 2018 to 340 in 2023 — while increasing the average revenue per distributor from ¥15 million (€1.9M) to ¥45 million (€5.8M) over the same period. The rationale: larger distributors with dedicated Siemens-trained service teams can provide faster maintenance (4-hour response target for Tier-1 hospitals, versus 24-hour for smaller partners) and handle complex VBP bid documentation.

Training has emerged as a differentiator. Siemens Healthineers operates six clinical training centers in China — in Beijing, Shanghai, Guangzhou, Chengdu, Xi’an, and Wuhan — that trained 28,000 Chinese radiologists and lab technicians in 2023 alone, up from 8,000 in 2019. The company estimates that each trained clinician generates ¥1.2 million (€154,000) in downstream consumables and service revenue over five years. In rural Gansu province, a pilot program deploying trained operators with ultrasound machines to 200 township clinics resulted in a 40% increase in usage rates within six months, demonstrating the revenue multiplier effect of embedded training.

Decision Framework: When to Build a WFOE vs. Use a Joint Venture

Siemens Healthineers’ experience yields a clear decision framework for MedTech companies entering China:

• If your core IP is in proprietary algorithms, software, or manufacturing processes that could be reversed-engineered — choose a WFOE. Siemens’ WFOE allowed it to retain 100% of its AI algorithm IP and manufacturing know-how for its high-end CT and MRI systems.
• If your product requires deep integration with China’s public hospital IT systems or government procurement networks — choose a joint venture with a state-owned enterprise or a leading Chinese hospital group. Siemens has used minority-stake JVs for its digital health platform business, where local partner guanxi (关系, guānxì) is critical for hospital data access.
• If your target market is Tier-3 and below cities — choose a WFOE with a local manufacturing base. The cost advantage of domestic production (30-40% lower Bill of Materials than imported units) is essential for VBP compliance.
• If your product is a first-in-class device requiring Chinese clinical trial data for global registration — choose a WFOE with a dedicated Chinese clinical trial team. Siemens’ Shanghai site now conducts early-phase trials that feed into European CE and FDA submissions.

For companies with annual China revenue below €50 million, the case suggests starting with a 100% owned representative office or WFOE trading company before investing in manufacturing. Siemens Healthineers’ own China journey began with a sales office in 1992, followed by a WFOE trading company in 2005, and only then its first manufacturing WFOE in 2010. The phased approach minimized political and regulatory risk while building market knowledge.

What Siemens Healthineers Does Differently: Three Strategic Insights

Three strategic choices distinguish Siemens Healthineers from peers like GE and Philips in China. First, the company intentionally prices its local-product lines 15-20% above domestic competitors (United Imaging, Neusoft), preserving a “premium value” perception among Chinese hospital administrators. In internal surveys, Siemens Healthineers found that 65% of hospital procurement directors prefer foreign brands at a 10-15% price premium if service-response times are guaranteed within 6 hours. The company has acted on this by building 78 regional service centers, compared to GE’s 52 and Philips’ 44.

Second, Siemens Healthineers has invested heavily in AI-assisted diagnostic tools that integrate with China’s national “Internet + Healthcare” platform (互联网+医疗健康, hùliánwǎng + yīliáo jiànkāng). Its AI-powered lung cancer screening software, trained on 150,000 Chinese CT scans, was certified by the NMPA in 2022 and is now installed in 400+ Chinese hospitals. The software increases radiologist throughput by 30% and generates ¥2,000 per hospital per month in subscription fees — a high-margin recurring revenue stream that is immune to VBP hardware price cuts.

Third, the company has co-invested with Chinese hospital groups in 12 diagnostic imaging centers under the “public-private partnership” model (公私合作, gōngsī hézuò), de-risking its balance sheet while securing equipment placements. These centers operate under 15-20 year contracts, guaranteeing Siemens Healthineers a minimum of ¥35 million (€4.5M) per center in consumables and service revenue over the contract term — effectively a recurring revenue annuity in a market where upfront device margins are shrinking.

NEXT STEPS

• Evaluate your WFOE vs. Joint Venture options: Read our complete guide How to Set Up a WFOE in China for Medical Device Companies, which includes a decision checklist tailored to MedTech IP sensitivity and revenue thresholds.
• Understand Volume-Based Procurement implications: Review VBP in China Medical Devices: Strategy Guide for Foreign Firms for a five-step framework to assess your product portfolio’s VBP readiness, including pricing sensitivity analysis and local sourcing requirements.
• Plan your NMPA registration pathway: Access NMPA Medical Device Classification and Registration for Foreign Companies, which maps the Green Channel eligibility criteria and provides a timeline template for domestic vs. import registration routes.

— China Gateway 360 —
Remote China market entry support, built around execution.